The regulator has reduced the maximum retail price of a new class of drugs, including statins, diabetes drugs, cardiovascular and combination drugs. The revised prices will have an impact on the manufacturers of these formulations, including Sun Pharma and Zydus Healthcare.from Industry-Economic Times
Read The Rest:economictimes...
